1. Globocan 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr, Accessed on 29/04/2019.
2. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderkaet D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386–422. doi: 10.1093/annonc/mdw235.
3. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS–102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909–19. doi: 10.1056/NEJMoa1414325.
4. Xu J, Kim TW, Shen L, Sriuranpong V1, Pan H1, Xu R, et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS–102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2018 Feb 1;36(4):350–358. doi: 10.1200/JCO.2017.74.3245.
5. Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, et al. Efficacy of trifluridine and tipiracil (TAS–102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clin Transl Oncol. 2017 Feb;19(2):227–235. doi: 10.1007/s12094–016–1528–7.
6. Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, et al. Trifluridine/Tipiracil (TAS–102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist. 2018 Oct;23(10):1178–1187. doi: 10.1634/theoncologist.2017–0573.
7. Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol. 2018 Jun;23(3):482–489. doi: 10.1007/s10147–017–1220–0.
8. Li Z, Xu Z, Huang Y, Zhao R, Cui Y, Zhou Y, et al. The predictive value and the correlation of peripheral absolute monocyte count, tumor-associated macrophage and microvessel density in patients with colon cancer. Medicine (Baltimore). 2018 May;97(21):e10759. doi: 10.1097/MD.0000000000010759.
9. Hu S, Zou Z, Li H, Zou G, Li Z, Xu J, et al. The Preoperative Peripheral Blood Monocyte Count Is Associated with Liver Metastasis and Overall Survival in Colorectal Cancer Patients. PLoS One. 2016 Jun 29;11(6):e0157486. doi: 10.1371/journal.pone.0157486.
10. Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, et al. Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg. 2007 May;11(5):596–602. doi: 10.1007/s11605–007–0140–0
11. Paik KY, Lee IK, Lee YS, Sung NY, Kwon TS. Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients. Cancer Res Treat. 2014 Jan;46(1):65–73. doi: 10.4143/crt.2014.46.1.65.
12. Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 2007; 96: 222–5. doi:10.1038/sj.bjc.6603558
13. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 2008; 98: 540–4. doi: 10.1002/jso.21154.
14. Shiu YC, Lin JK, Huang CJ, Jiang JK, Wang LW, Huang HC, et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum. 2008 Apr;51(4):443–9. doi: 10.1007/s10350–007–9133-z.
15. Kersten C, Louhimo J, Ålgars A, Lahdesmaki A, Cvancerova M, Stenstedt K, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol. 2013 Nov;52(8):1691–8. doi: 10.3109/0284186X.2013.835494.
16. Kim WR, Han YD, Min BS. C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2018 Dec;25(13):3898–3905. doi: 10.1245/s10434–018–6828–4.
17. Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, et al. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS–102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer. 2016 Jul 13;16:467. doi: 10.1186/s12885–016–2491-y.
18. Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, et al. Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS–102. Clin Colorectal Cancer. 2017 Mar;16(1):51–57. doi: 10.1016/j.clcc.2016.07.005.
19. Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol. 2017 Mar 1;28(3):555–561. doi: 10.1093/annonc/mdw627.
20. Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, et al. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 Dec;17(4):e687-e697. doi: 10.1016/j.clcc.2018.07.004.